HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk ...

Please provide your email address to receive an email when new articles are posted on . Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after ...

The FDA approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such ...

On Friday, Dr. Reddy's Laboratories and its subsidiaries informed the bourses, after-market hours that the company launched Colchicine tablets USP in the US markets. The drug is available in 0.6 mg ...

WOBURN, Mass.--(BUSINESS WIRE)--ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S.

Dear Dr. Roach: I’m a 78-year-old man with a stent and a blockage in one of the arteries to my heart. I am on a low-fat diet and take ramipril for cholesterol. My levels are very good (total ...

URL Pharma, Inc., today announced that the FDA has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with Colcrys (colchicine). These ...

PHILADELPHIA, PA—Colchicine, given orally prior to PCI in an all-comers population, does not reduce procedure-related myocardial injury, but does appear to attenuate the inflammatory response, results ...